---

Therapeutic potential and pharmacological properties of Indian herbs for the management of SARS-COV-2 coronavirus disease: A research based review

---

Review Article

Author Details : Abinash Satapathy, Trilochan Satapathy, Harsha Sahu, Saraswati Prasad Mishra, Shweta Dutta*

Volume : 9, Issue : 3, Year : 2022

Article Page : 143-149

https://doi.org/10.18231/j.ijpp.2022.026

Suggest article by email

Get Permission

---

Abstract

Corona virus (COVs) are RNA virus that comes from the family COVs are pathogenic to animals as well as human beings and can cause ailment related to respiratory system such as severe acute respiratory syndrome (SARS) and COVID-19. However treatment of COVID-19 is one of the major area of concern as there are no appropriate treatment options available, however few herbal products are being used to boost the immunity of patients and in turn prevent the occurrence of infection. Historically India has always been rich with plants and is known to use herbs and plants in traditional system of healing. India has distinct traditional system of medicine called AYUSH that represents Ayurveda, Yoga, Unani, Siddha and homeopathy. This traditional system of medicine can be used to fight against COVID-19 pandemic. Present study describes about different herbs and plants of Indian origin that can be used for effective management COVID-19 and in future that can act as potential candidate for development of improved drugs for therapy of COVID-19 infection.

Keywords: Herbs, Corona virus, SARS, Pandemic, AYUSH 

How to cite : Satapathy A, Satapathy T, Sahu H, Mishra S P, Dutta S, Therapeutic potential and pharmacological properties of Indian herbs for the management of SARS-COV-2 coronavirus disease: A research based review. Indian J Pharm Pharmacol 2022;9(3):143-149

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.